HIV viral load: the myth of the undetectable?PILLAY, Deenan.Reviews in medical virology. 2002, Vol 12, Num 6, pp 391-396, issn 1052-9276, 6 p.Article

Current patterns in the epidemiology of primary HIV drug resistance in North America and EuropePILLAY, Deenan.Antiviral therapy (London). 2004, Vol 9, Num 5, pp 695-702, issn 1359-6535, 8 p.Article

The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected populationPILLAY, Deenan.Antiviral therapy (London). 2001, Vol 6, pp 15-24, issn 1359-6535, SUP3Conference Paper

HIV resistance and the developing worldRAVINDRA KUMAR GUPTA; PILLAY, Deenan.International journal of antimicrobial agents. 2007, Vol 29, Num 5, pp 510-517, issn 0924-8579, 8 p.Article

Transmission of HIV-1 drug resistanceTANG, Julian W; PILLAY, Deenan.Journal of clinical virology. 2004, Vol 30, Num 1, pp 1-10, issn 1386-6532, 10 p.Article

The priorities for antiviral drug resistance surveillance and researchPILLAY, Deenan.Journal of antimicrobial chemotherapy (Print). 2007, Vol 60, issn 0305-7453, i57-i58, SUP1Article

Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 IntegraseMYERS, Richard E; PILLAY, Deenan.Journal of virology. 2008, Vol 82, Num 18, pp 9228-9235, issn 0022-538X, 8 p.Article

Effect of isolated V1181 mutation in reverse transcriptase on response to first-line antiretroviral therapyMIHAILIDIS, Christos; DUNN, David; PILLAY, Deenan et al.AIDS (London). 2008, Vol 22, Num 3, pp 427-430, issn 0269-9370, 4 p.Article

Solid organ transplantation in patients with HIV infectionGOW, Paul J; PILLAY, Deenan; MUTIMER, David et al.Transplantation. 2001, Vol 72, Num 2, pp 177-181, issn 0041-1337Article

Investigation of HIV-1 transmission events by phylogenetic methods : Requirement for scientific rigourHUE, Stéphane; CLEWLEY, Jonathan P; CANE, Patricia A et al.AIDS (London). 2005, Vol 19, Num 4, pp 449-450, issn 0269-9370, 2 p.Article

HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapyHUE, Stéphane; CLEWLEY, Jonathan P; CANE, Patricia A et al.AIDS (London). 2004, Vol 18, Num 5, pp 719-728, issn 0269-9370, 10 p.Article

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsWINSTON, Alan; MANDALIA, Sundhiya; PILLAY, Deenan et al.AIDS (London). 2002, Vol 16, Num 15, pp 2087-2089, issn 0269-9370, 3 p.Article

Analysis of HIV-1 variation in blood and semen during treatment and treatment interruptionCHOUDHURY, Bhudipa; PILLAY, Deenan; TAYLOR, Stephen et al.Journal of medical virology. 2002, Vol 68, Num 4, pp 467-472, issn 0146-6615, 6 p.Article

Dynamics of seminal plasma HIV-1 decline after antiretroviral treatmentTAYLOR, Stephen; FERGUSON, Neil M; CANE, Patricia A et al.AIDS (London). 2001, Vol 15, Num 3, pp 424-426, issn 0269-9370Article

HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysisBUCKTON, Andrew J; HARRIS, Ross J; PILLAY, Deenan et al.Antiviral therapy (London). 2011, Vol 16, Num 1, pp 9-16, issn 1359-6535, 8 p.Article

Hare TRIM5α Restricts Divergent Retroviruses and Exhibits Significant Sequence Variation from Closely Related Lagomorpha TRIMS GenesFLETCHER, Adam J; HUE, Stéphane; SCHALLER, Torsten et al.Journal of virology. 2010, Vol 84, Num 23, pp 12463-12468, issn 0022-538X, 6 p.Article

Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive IndividualsHUE, Stéphane; GIFFORD, Robert J; DUNN, David et al.Journal of virology. 2009, Vol 83, Num 6, pp 2645-2654, issn 0022-538X, 10 p.Article

ARHAI: antiviral resistanceTONG, C. Y. William; CANE, Patricia A; PILLAY, Deenan et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, issn 0305-7453, i65-i72, SUP1Article

The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United KingdomGREEN, Hannah; TILSTON, Peter; FEARNHILL, Esther et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 2, pp 196-204, issn 1525-4135, 9 p.Article

Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1MATTHEWS, Gail V; PILLAY, Deenan; CANE, Patricia et al.Clinical infectious diseases. 2001, Vol 33, Num 12, pp 2049-2054, issn 1058-4838Article

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapyBRIDGET FERNS, Ruth; KIRK, Stuart; BENNETT, Julie et al.AIDS (London). 2009, Vol 23, Num 16, pp 2161-2166, issn 0269-9370, 6 p.Article

Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy : A Systematic Review of Clinical Trials. CommentaryGUPTA, Ravindra; HILL, Andrew; SAWYER, Anthony W et al.Clinical infectious diseases. 2008, Vol 47, Num 5, pp 712-725, issn 1058-4838, 14 p.Article

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptaseWINSTON, Alan; POZNIAK, Anton; MANDALIA, Sundhiya et al.AIDS (London). 2004, Vol 18, Num 6, pp 949-951, issn 0269-9370, 3 p.Article

Persistence of HIV-1 Transmitted Drug Resistance MutationsCASTRO, Hannah; PILLAY, Deenan; CANE, Patricia et al.The Journal of infectious diseases. 2013, Vol 208, Num 9, pp 1459-1463, issn 0022-1899, 5 p.Article

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maravirocARMSTRONG-JAMES, Darius; STEBBING, Justin; SCOURFIELD, Andrew et al.Antiviral research. 2010, Vol 86, Num 2, pp 224-226, issn 0166-3542, 3 p.Article